Irritable bowel syndrome - Pipeline Insight, 2024

Irritable bowel syndrome - Pipeline Insight, 2024

DelveInsight’s, “Irritable bowel syndrome - Pipeline Insight, 2024,” report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Irritable bowel syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Irritable bowel syndrome Understanding

Irritable bowel syndrome: Overview

Irritable bowel syndrome (IBS) is a group of symptoms that occur together, including repeated pain in your abdomen and changes in your bowel movements, which may be diarrhea, constipation, or both. With IBS, you have these symptoms without any visible signs of damage or disease in your digestive tract. The most common symptoms of irritable bowel syndrome (IBS) are pain in your abdomen, often related to your bowel movements, and changes in your bowel movements. These changes may be diarrhea, constipation, or both, depending on what type of IBS you have. To diagnose irritable bowel syndrome (IBS), doctors review the symptoms and the medical and family history and perform a physical exam. The doctor will look for a certain pattern in the symptoms. In some cases, doctors may order tests to rule out other health problems.

""Irritable bowel syndrome - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Irritable bowel syndrome pipeline landscape is provided which includes the disease overview and Irritable bowel syndrome treatment guidelines. The assessment part of the report embraces, in depth Irritable bowel syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Irritable bowel syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Irritable bowel syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Irritable bowel syndrome.

Irritable bowel syndrome Emerging Drugs Chapters

This segment of the Irritable bowel syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Irritable bowel syndrome Emerging Drugs

• ORP-101: OrphoMed

ORP-101 is a new chemical entity designed to confer peripheral partial μ agonist and full κ receptor antagonist activity, enabling treatment of both IBS-D symptoms of dysmotility and pain without the risk of sphincter of Oddi spasm or pancreatitis. ORP-101 has been shown in preclinical studies to not cross the blood-brain barrier. ORP-101 successfully completed Phase 1 clinical trials and was granted FDA Fast Track designation in 2018. Regulatory path to NDA has been agreed with the FDA. Currently, it is in Phase II stage of clinical trial evaluation to treat Irritable bowel syndrome.

• Blautix: 4D Pharma

Blautix® is a single strain Live Biotherapeutic product (LBP), being developed as a treatment for both IBS-C and IBS-D. Pre-clinical studies demonstrated its ability to address visceral hypersensitivity and other symptoms of IBS and increase microbiome diversity. A Phase I study in healthy volunteers and IBS patients showed that Blautix® was well tolerated and an improvement in symptoms was also reported relative to placebo. The Phase II BHT-II-002 trial demonstrated an impact on overall response with regards to bowel habit and abdominal pain in IBS-C and IBS-D. Blautix® was well tolerated, with a safety profile comparable to placebo.

Further product details are provided in the report……..

Irritable bowel syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Irritable bowel syndrome drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Irritable bowel syndrome

There are approx. 24+ key companies which are developing the therapies for Irritable bowel syndrome. The companies which have their Irritable bowel syndrome drug candidates in the most advanced stage, i.e. phase II include OrphoMed.

• Phases

DelveInsight’s report covers around 24+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Irritable bowel syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Irritable bowel syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Irritable bowel syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Irritable bowel syndrome drugs.

Irritable bowel syndrome Report Insights

• Irritable bowel syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Irritable bowel syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Irritable bowel syndrome drugs?
• How many Irritable bowel syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Irritable bowel syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Irritable bowel syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Irritable bowel syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Arena Pharmaceuticals
• 4D Pharma
• OrphoMed
• Boston Pharmaceuticals
• RedHill Biopharma Limited
• Takeda
• Cosmo Technologies
• CinRx Pharma
• Rottapharm
• Synthetic Biologics
• Biomica
• Metacrine
• MGC Pharma
• Napo Pharmaceuticals
• Novome Biotechnologies
• Renexxion
• Sentia Medical Sciences
• Serentrix LLC
• Vitality Biopharma

Key Products

• Olorinab
• Blautix
• ORP-101
• BOS-589
• BEKINDA
• Mesalamine
• Rifamycin controlled-release
• CIN 103
• Crofelemer
• RQ-00310941
• AAT 730